Total Payments
$215,488
2024 Payments
$31,471
Companies
23
Transactions
344
Medicare Patients
1,762
Medicare Billing
$399,179
Payment Breakdown by Category
Other$170,244 (79.0%)
Travel$32,783 (15.2%)
Food & Beverage$8,766 (4.1%)
Consulting$3,600 (1.7%)
Education$96.36 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $170,244 | 85 | 79.0% |
| Travel and Lodging | $32,783 | 79 | 15.2% |
| Food and Beverage | $8,766 | 175 | 4.1% |
| Consulting Fee | $3,600 | 1 | 1.7% |
| Education | $96.36 | 4 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $96,303 | 111 | $0 (2023) |
| Bayer Healthcare Pharmaceuticals Inc. | $46,101 | 69 | $0 (2024) |
| Relypsa, Inc. | $39,989 | 70 | $0 (2020) |
| Vifor Pharma, Inc. | $31,873 | 46 | $0 (2024) |
| GlaxoSmithKline, LLC. | $266.72 | 13 | $0 (2023) |
| Mallinckrodt LLC | $128.48 | 2 | $0 (2018) |
| Novo Nordisk Inc | $109.80 | 1 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $98.05 | 4 | $0 (2024) |
| Aurinia Pharma U.S., Inc. | $83.29 | 3 | $0 (2023) |
| Mallinckrodt Hospital Products Inc. | $64.80 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $31,471 | 53 | Bayer Healthcare Pharmaceuticals Inc. ($27,843) |
| 2023 | $20,078 | 51 | Bayer Healthcare Pharmaceuticals Inc. ($18,048) |
| 2022 | $18,607 | 39 | Vifor Pharma, Inc. ($18,260) |
| 2021 | $8,833 | 13 | Vifor Pharma, Inc. ($8,726) |
| 2020 | $3,428 | 5 | Relypsa, Inc. ($3,428) |
| 2019 | $56,043 | 77 | Novartis Pharmaceuticals Corporation ($28,727) |
| 2018 | $49,574 | 63 | Novartis Pharmaceuticals Corporation ($40,217) |
| 2017 | $27,454 | 43 | Novartis Pharmaceuticals Corporation ($27,333) |
All Payment Transactions
344 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $27.20 | General |
| Category: Cardio-renal | ||||||
| 12/04/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,255.00 | General |
| Category: Cardio-renal | ||||||
| 11/23/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,255.00 | General |
| Category: Cardio-renal | ||||||
| 11/21/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $28.42 | General |
| Category: Diabetes | ||||||
| 11/14/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $27.71 | General |
| Category: Cardio-renal | ||||||
| 11/08/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $103.86 | General |
| Category: Cardio-renal | ||||||
| 11/06/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $31.87 | General |
| Category: Rare Disease | ||||||
| 10/17/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $27.67 | General |
| 10/16/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $18.53 | General |
| Category: Phosphate binder for ESRD | ||||||
| 10/15/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $19.69 | General |
| Category: DIABETES | ||||||
| 10/07/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $18.33 | General |
| Category: Nephrology | ||||||
| 10/03/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $14.59 | General |
| Category: Cardio-renal | ||||||
| 09/13/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $30.34 | General |
| Category: Cardio-renal | ||||||
| 09/11/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,255.00 | General |
| Category: Cardio-renal | ||||||
| 09/10/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $20.68 | General |
| Category: DIABETES | ||||||
| 08/23/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $121.82 | General |
| Category: Cardio-renal | ||||||
| 08/15/2024 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $26.88 | General |
| Category: Hyperkalemia | ||||||
| 08/12/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $26.02 | General |
| Category: Cardio-renal | ||||||
| 07/24/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $21.76 | General |
| Category: Diabetes | ||||||
| 07/18/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $109.80 | General |
| 07/12/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,332.50 | General |
| Category: Cardio-renal | ||||||
| 06/28/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $21.23 | General |
| Category: Cardio-renal | ||||||
| 06/20/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,255.00 | General |
| Category: Cardio-renal | ||||||
| 06/12/2024 | Vifor Pharma, Inc. | Veltassa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,760.00 | General |
| Category: Hyperkalemia | ||||||
| 06/12/2024 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $20.79 | General |
| Category: Hyperkalemia | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 513 | 868 | $375,725 | $101,768 |
| 2022 | 9 | 667 | 1,242 | $677,780 | $158,357 |
| 2021 | 7 | 582 | 1,071 | $564,595 | $139,054 |
Total Patients
1,762
Total Services
3,181
Medicare Billing
$399,179
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 18 | 128 | $230,400 | $35,581 | 15.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 174 | 298 | $55,130 | $27,323 | 49.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 93 | 143 | $27,170 | $13,000 | 47.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 77 | 79 | $28,045 | $10,161 | 36.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 78 | 147 | $19,110 | $9,095 | 47.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 47 | 47 | $14,100 | $5,714 | 40.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 12 | 12 | $1,560 | $846.82 | 54.3% |
| 81002 | Urinalysis, manual test | Office | 2023 | 14 | 14 | $210.00 | $47.74 | 22.7% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 35 | 240 | $432,000 | $66,983 | 15.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 224 | 419 | $77,515 | $32,465 | 41.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 121 | 129 | $45,795 | $19,593 | 42.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 133 | 234 | $30,420 | $12,999 | 42.7% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2022 | 22 | 46 | $55,200 | $10,570 | 19.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 63 | 103 | $19,570 | $9,252 | 47.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 37 | 37 | $11,100 | $4,540 | 40.9% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2022 | 20 | 22 | $4,620 | $1,261 | 27.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 12 | 12 | $1,560 | $693.74 | 44.5% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Office | 2021 | 59 | 180 | $324,000 | $51,937 | 16.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 159 | 340 | $62,900 | $27,818 | 44.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 104 | 113 | $40,115 | $17,549 | 43.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 141 | 293 | $38,090 | $16,541 | 43.4% |
| 90961 | Dialysis services (2-3 physician visits per month), patient 20 years of age and older | Office | 2021 | 44 | 66 | $79,200 | $15,787 | 19.9% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 48 | 48 | $14,400 | $6,189 | 43.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 27 | 31 | $5,890 | $3,233 | 54.9% |
About Dr. Harry Goss, MD
Dr. Harry Goss, MD is a Nephrology healthcare provider based in Austin, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1508832437.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Harry Goss, MD has received a total of $215,488 in payments from pharmaceutical and medical device companies, with $31,471 received in 2024. These payments were reported across 344 transactions from 23 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($170,244).
As a Medicare-enrolled provider, Goss has provided services to 1,762 Medicare beneficiaries, totaling 3,181 services with total Medicare billing of $399,179. Data is available for 3 years (2021–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location Austin, TX
- Active Since 02/28/2006
- Last Updated 03/26/2009
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1508832437
Products in Payments
- ENTRESTO (Drug) $96,277
- Veltassa (Drug) $60,090
- Kerendia (Drug) $46,101
- ACTHAR (Biological) $193.28
- BENLYSTA (Biological) $165.28
- JESDUVROQ (Drug) $101.44
- ULTOMIRIS (Biological) $98.05
- JARDIANCE (Drug) $90.55
- LUPKYNIS (Drug) $83.29
- Velphoro (Drug) $39.60
- TARPEYO (Drug) $31.93
- Korsuva (Drug) $29.21
- CYSTADROPS (Drug) $22.76
- JYNARQUE (Drug) $22.58
- RENVELA (Drug) $21.85
- Auryxia (Drug) $20.99
- Sensipar (Drug) $18.67
- Parsabiv (Biological) $18.01
- FARXIGA (Drug) $17.80
- VYVANSE (Drug) $17.27
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Austin
Dr. Michelle Lubetzky, Md, MD
Nephrology — Payments: $33,694
Nephrology $33,694
Judith Betts, Md, MD
Nephrology — Payments: $13,254
Nephrology $13,254
Margaret Cook, Md, MD
Nephrology — Payments: $10,676
Nephrology $10,676
Vincent Tjia, Md, MD
Nephrology — Payments: $7,190
Nephrology $7,190
Dr. Andrew Pelphrey, M.d, M.D
Nephrology — Payments: $6,428
Nephrology $6,428
Sujatha Venkatesh, Md, MD
Nephrology — Payments: $5,559
Nephrology $5,559